AbbVie Inc (ABBV)vsElevai Labs, Inc. Common Stock (ELAB)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
ELAB
Elevai Labs, Inc. Common Stock
$4.52
-1.74%
HEALTHCARE · Cap: $4.20M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2496739% more annual revenue ($64.39B vs $2.58M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
ELAB
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for ELAB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : ELAB
The strongest argument for ELAB centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : ELAB
The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 30/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Elevai Labs, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Elevai Labs, Inc. (Ticker: ELAB) is an innovative technology firm at the forefront of artificial intelligence and machine learning, primarily catering to the healthcare and finance sectors. By leveraging sophisticated data analytics, the company empowers organizations to extract actionable insights from intricate datasets, thus enhancing operational efficiencies and supporting strategic decision-making. Positioned strategically within a dynamic technology landscape, Elevai Labs is well-prepared to harness emerging market trends for growth, underscoring its commitment to advancing AI technologies and solidifying its role as a significant player with strong potential for sustainable development and competitive advantage.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?